Sun Pharmaceutical Industries Limited (SUNPHARMA) — Board Meeting | 31 July 2025(2 announcements)

· NSE 🟡 Notable ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable ✨ Positive 📄 PDF

Sun Pharmaceutical's 33rd AGM approved eight resolutions including financial statements, a ₹5.50 per share final dividend, and leadership transitions. Kirti Ganorkar was appointed Managing Director succeeding Dilip Shanghvi, while Vidhi Shanghvi joined as Whole-time Director. FY25 showed strong performance: revenue grew 9.0% to ₹520 billion, EBITDA surged 17.3% to ₹153 billion (29% margin), and adjusted net profit rose 19.0% to ₹120 billion. Global Specialty revenue jumped 17.1% to US$1,216 million. The company completed Checkpoint Therapeutics acquisition and launched Leqselvi for alopecia areata.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

Sun Pharmaceutical reported Q1 FY2026 standalone revenue of ₹56,019.6 million and net profit of ₹7,535.3 million. Consolidated revenue reached ₹138,514 million with net profit of ₹22,928.7 million. The Board approved ₹2,876.4 million exceptional charge for SCD-044 drug discontinuation. Key acquisitions include Checkpoint Therapeutics (June 2025) and Antibe Therapeutics (March 2025). India formulations grew 13.9% YoY. Significant committee restructuring occurred with Sudhir Valia retiring at the 33rd AGM.

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day